<DOC>
	<DOCNO>NCT00487253</DOCNO>
	<brief_summary>The purpose randomize , open label clinical trial determine oral miltefosine safe effective alternative , compare parenteral meglumine antimoniate treatment pediatric Cutaneous cause L. Viannia species Colombia .</brief_summary>
	<brief_title>Oral Miltefosine Treatment Pediatric Cutaneous Leishmaniasis Colombia</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>2 12 year age ( inclusive ) Parasitologically confirm CL Availability receive supervise treatment 28 day ( i.e. , directly observe therapy , ensure therapy appropriately administer received e.g. , miltefosine `` swallow '' ) Availability return followup visit least 6 month treatment initiate Weight 10kg Previous use SbV , miltefosine antileishmanial therapy Simultaneous mucosal lesion suggestive proven mucosal leishmaniasis If girl , ability reproduce ( history menarche ) Relative absolute contraindication use SbV drug miltefosine , include history cardiac , renal hepatic disease Patients pretreatment haemoglobin &lt; 10g/dl blood urea nitrogen ( BUN ) , serum creatinine , ALT , AST amylase value exceed upper limit normal If living Malaria endemic area ( eg . Tumaco ) : A positive malaria thick smear</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Cutaneous Leishmaniasis</keyword>
	<keyword>Leishmania Viannia</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Randomized</keyword>
	<keyword>Colombia</keyword>
</DOC>